Published in Ann Pharmacother on October 01, 2001
Statin adverse effects : a review of the literature and evidence for a mitochondrial mechanism. Am J Cardiovasc Drugs (2008) 2.62
Statin intolerance - an attempt at a unified definition. Position paper from an International Lipid Expert Panel. Arch Med Sci (2015) 1.25
Insomnia and chronic heart failure. Heart Fail Rev (2008) 0.86
Sleep changes following statin therapy: a systematic review and meta-analysis of randomized placebo-controlled polysomnographic trials. Arch Med Sci (2015) 0.80
Improvement in sleep apnoea associated with switch from simvastatin to pravastatin. BMJ Case Rep (2009) 0.77
Atorvastatin may cause nightmares. BMJ (2006) 0.76
Left superior vena cava persistence in patients undergoing pacemaker or cardioverter-defibrillator implantation: a 10-year experience. Chest (2001) 5.12
Efficacy of implantable cardioverter-defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy. N Engl J Med (2000) 4.04
Selective expression of an interleukin-12 receptor component by human T helper 1 cells. J Exp Med (1997) 3.57
Thromboxane antagonism and cough induced by angiotensin-converting-enzyme inhibitor. Lancet (1997) 3.19
Transcript imaging of the development of human T helper cells using oligonucleotide arrays. Nat Genet (2000) 2.71
Amyloid deposition as a cause of atrial remodelling in persistent valvular atrial fibrillation. Eur Heart J (2004) 1.66
Effectiveness of loading oral flecainide for converting recent-onset atrial fibrillation to sinus rhythm in patients without organic heart disease or with only systemic hypertension. Am J Cardiol (1992) 1.66
The role of Stat4 in species-specific regulation of Th cell development by type I IFNs. J Immunol (1998) 1.65
Prognosis of asymptomatic patients with hypertrophic cardiomyopathy and nonsustained ventricular tachycardia. Circulation (1994) 1.61
Non-invasive evaluation of the myocardial substrate of cardiac amyloidosis by gadolinium cardiac magnetic resonance. Heart (2005) 1.57
Wide spectrum of presentation and variable outcomes of isolated left ventricular non-compaction. Heart (2006) 1.53
A multicentre, double-blind randomized crossover comparative study on the efficacy and safety of dofetilide vs sotalol in patients with inducible sustained ventricular tachycardia and ischaemic heart disease. Eur Heart J (2001) 1.46
Malignant vasovagal syncope: a randomised trial of metoprolol and clonidine. Heart (1997) 1.42
Antiarrhythmic benefits of dual chamber stimulation with rate-response in patients with paroxysmal atrial fibrillation and chronotropic incompetence: a prospective, multicentre study. Europace (1999) 1.41
Coronary stenting with the half (disarticulated) Palmaz-Schatz stent: immediate results and six-month follow-up. Cathet Cardiovasc Diagn (1997) 1.40
[Diagnostic contribution of magnetic resonance in clinically suspected arrhythmogenic dysplasia of the right ventricle]. G Ital Cardiol (1996) 1.39
Antibodies to the IL-12 receptor beta 2 chain mark human Th1 but not Th2 cells in vitro and in vivo. J Immunol (1999) 1.15
Mutation analysis of the lamin A/C gene (LMNA) among patients with different cardiomuscular phenotypes. J Med Genet (2003) 1.13
Effectiveness of a continuous quality improvement program on colonoscopy practice. Endoscopy (2007) 1.11
Evidence of a partial escape of renin-angiotensin-aldosterone blockade in patients with acute myocardial infarction treated with ACE inhibitors. J Clin Pharmacol (1993) 1.10
A controlled study on oral propafenone versus digoxin plus quinidine in converting recent onset atrial fibrillation to sinus rhythm. Int J Cardiol (1994) 1.09
Randomized crossover comparison of right atrial appendage pacing versus interatrial septum pacing for prevention of paroxysmal atrial fibrillation in patients with sinus bradycardia. Am Heart J (2001) 1.09
Pharmacokinetic studies of 4'-epi-doxorubicin in cancer patients with normal and impaired renal function and with hepatic metastases. Cancer Treat Rep (1982) 1.08
A randomized placebo-controlled trial of fluvastatin for prevention of restenosis after successful coronary balloon angioplasty; final results of the fluvastatin angiographic restenosis (FLARE) trial. Eur Heart J (1999) 1.07
A novel Alu-like element rearranged in the dystrophin gene causes a splicing mutation in a family with X-linked dilated cardiomyopathy. Am J Hum Genet (1998) 1.06
Opposite effects of interleukin 10 common gene polymorphisms in cardiovascular diseases and in successful ageing: genetic background of male centenarians is protective against coronary heart disease. J Med Genet (2004) 1.04
Pulmonary arterial hypertension associated to connective tissue diseases. Lupus (2005) 1.03
Laminopathies: many diseases, one gene. Report of the first Italian Meeting Course on Laminopathies. Acta Myol (2011) 1.01
Conversion of recent-onset atrial fibrillation by a single oral loading dose of propafenone or flecainide. Am J Cardiol (1994) 0.99
Dynamic electrophysiological behavior of human atria during paroxysmal atrial fibrillation. Circulation (1995) 0.99
Benefits in projected pacemaker longevity and in pacing related costs conferred by automatic threshold tracking. Pacing Clin Electrophysiol (2000) 0.99
Evaluation of the pulse-contour method of determining stroke volume in man. Circulation (1972) 0.98
Atrial premature beats coupling interval determines lone paroxysmal atrial fibrillation onset. Int J Cardiol (1992) 0.97
Transvenous low energy internal cardioversion for atrial fibrillation: a review of clinical applications and future developments. Pacing Clin Electrophysiol (2001) 0.96
AF burden is important - fact or fiction? Int J Clin Pract (2014) 0.96
Planning palliative or terminal care: the dilemma of doctors' prognoses in terminally ill cancer patients. Ann Oncol (2002) 0.95
Oral propafenone to convert recent-onset atrial fibrillation in patients with and without underlying heart disease. A randomized, controlled trial. Ann Intern Med (1997) 0.94
Role of pharmacologic tests in the treatment of primary pulmonary hypertension. Am J Cardiol (1995) 0.92
Epirubicin and doxorubicin comparative metabolism and pharmacokinetics. A cross-over study. Cancer Chemother Pharmacol (1988) 0.92
Clinical value of multidetector CT coronary angiography as a preoperative screening test before non-coronary cardiac surgery. Heart (2006) 0.92
Conversion of recent-onset atrial fibrillation to sinus rhythm: effects of different drug protocols. Pacing Clin Electrophysiol (1998) 0.91
Impact of consistent atrial pacing algorithm on premature atrial complexe number and paroxysmal atrial fibrillation recurrences in brady-tachy syndrome: a randomized prospective cross over study. J Interv Card Electrophysiol (2001) 0.91
The determination of gemcitabine and 2'-deoxycytidine in human plasma and tissue by APCI tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci (2006) 0.90
Enhanced thrombolytic efficacy and reduction of infarct size by simultaneous infusion of streptokinase and heparin. Br Heart J (1990) 0.90
[Paroxysmal atrial fibrillation: study of the pattern of onset using dynamic electrocardiography]. Cardiologia (1989) 0.89
Medical therapy of pulmonary hypertension. The prostacyclins. Clin Chest Med (2001) 0.88
Multicenter randomized clinical trial on high-dose epirubicin plus cis-platinum versus vinorelbine plus cis-platinum in advanced non small cell lung cancer. Lung Cancer (1998) 0.87
On the value of the activated clotting time for monitoring heparin therapy in acute coronary syndromes. Am J Cardiol (1993) 0.85
Primary pulmonary hypertension: insights into pathogenesis from epidemiology. Chest (1998) 0.85
Interplay between methylenetetrahydrofolate reductase gene polymorphism 677C-->T and serum folate levels in determining hyperhomocysteinemia in heart transplant recipients. J Heart Lung Transplant (2001) 0.85
Paroxysmal atrial fibrillation in sleep. Sleep (1997) 0.85
Autocrine and intracrine signaling for cardiogenesis in embryonic stem cells: a clue for the development of novel differentiating agents. Handb Exp Pharmacol (2006) 0.85
Evaluation by cardiopulmonary exercise test of DDDR versus DDD pacing. Pacing Clin Electrophysiol (1992) 0.84
Interleukin-6 gene polymorphism is an age-dependent risk factor for myocardial infarction in men. Int J Immunogenet (2005) 0.84
Efficacy and tolerability in fully conscious patients of transvenous low-energy internal atrial cardioversion for atrial fibrillation. Am J Cardiol (1998) 0.84
Psychological evaluation after cardiac transplantation: the integration of different criteria. Psychother Psychosom (2001) 0.83
Leukocyte subsets and cortisol serum levels in patients with migraine without aura and chronic tension-type headache. Cephalalgia (1994) 0.83
Atrial fibrillation recurrence after internal cardioversion: prognostic importance of electrophysiological parameters. Heart (2002) 0.83
Low energy internal atrial cardioversion in atrial fibrillation lasting more than a year. Pacing Clin Electrophysiol (1999) 0.83
The new clinical trials on pharmacological treatment in pulmonary arterial hypertension. Eur Respir J (2002) 0.82
Electrophysiological effects of flecainide and propafenone on atrial fibrillation cycle and relation with arrhythmia termination. Heart (1999) 0.82
Genetic heterogeneity of hypertrophic cardiomyopathy. Int J Cardiol (1985) 0.82
Medroxyprogesterone acetate (MAP) relative bioavailability after single high-dose administration in cancer patients. Cancer Treat Rep (1982) 0.82
Comparative crossover trial of two intravenous doses of granisetron (1 mg vs 3 mg) + dexamethasone in the prevention of acute cis-platinum-induced emesis. Anticancer Res (1998) 0.82
Use of red blood cell transfusion in palliative care services: is it still up to date or is cancer-related anaemia controlled better with erythropoietic agents? Ann Oncol (2004) 0.82
Favorable effects of flecainide in transvenous internal cardioversion of atrial fibrillation. J Am Coll Cardiol (1999) 0.82
Electrical cardioversion for persistent atrial fibrillation or atrial flutter in clinical practice: predictors of long-term outcome. Int J Clin Pract (2007) 0.81
Results of coronary stenting for unstable versus stable angina pectoris. Am J Cardiol (1997) 0.81
Renal haemodynamics after chronic treatment with labetalol and propranolol. Br J Clin Pharmacol (1982) 0.81
Comparison of three devices for measuring blood pressure. Stat Med (1985) 0.81
Reduced oxidative activity of circulating neutrophils in patients after myocardial infarction. Cell Biochem Funct (1990) 0.81
Differential effect of everolimus on progression of early and late cardiac allograft vasculopathy in current clinical practice. Am J Transplant (2013) 0.81
CEA, MCA, CA 15.3 and CA 549 and their combinations in expressing and monitoring metastatic breast cancer: a prospective comparative study. Eur J Cancer (1995) 0.81
ACE inhibitor-induced cough in hypertensive type 2 diabetic patients. Diabetes Care (1999) 0.81
Comparison of efficacy of low molecular weight heparin (parnaparin) with that of unfractionated heparin in the presence of activated platelets in healthy subjects. Am J Cardiol (1993) 0.81
Long term outcome in patients with silent versus symptomatic ischaemia during dobutamine stress echocardiography. Heart (2005) 0.81
Drugs, surgery, cardioverter defibrillator: a decision based on the clinical problem. Pacing Clin Electrophysiol (1993) 0.80
The metabolic effects of enalapril. Clin Exp Hypertens A (1987) 0.80
Benefit of adding low molecular weight heparin to the conventional treatment of stable angina pectoris. A double-blind, randomized, placebo-controlled trial. Circulation (1993) 0.80
Tocainide and metoprolol: an efficacious therapeutic combination in the treatment of premature ventricular beats. Clin Cardiol (1989) 0.79
Comparative haemodynamic effects of transdermal vs intravenous nitroglycerin in acute myocardial infarction with elevated pulmonary artery wedge pressure. Eur Heart J (1990) 0.79
Pseudoxanthoma elasticum: a rare cause of gastrointestinal bleeding. Am J Gastroenterol (1996) 0.79
High-performance liquid chromatographic analysis of tamoxifen and major metabolites in human plasma. J Chromatogr (1983) 0.79
Epirubicin pharmacokinetics after intrahepatic arterial and intraperitoneal administration. Drugs Exp Clin Res (1985) 0.79
Evaluation of atrial refractoriness and atrial fibrillation inducibility immediately after internal cardioversion in patients with chronic persistent atrial fibrillation. Cardiovasc Drugs Ther (1999) 0.79